文献速递血栓与止血

直接口服抗凝药与低分子肝素在原发性和转移性脑癌中的比较:一项荟萃分析与系统综述

Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review.
PubMed 文献 · J Thromb Haemost · 2023-10-21

该荟萃分析与系统综述纳入10项回顾性研究(n=1638),比较脑癌患者使用直接口服抗凝药(DOACs)与低分子肝素(LMWH)的颅内出血(ICH)风险。汇总风险比(RR)为0.65(95%CI 0.36-1.17;P=.15;I2=50%),原发性脑癌亚组DOACs的ICH风险降低(RR 0.35;95%CI 0.18-0.69;P=.003;I2=0%),转移性脑癌亚组无差异(RR 1.05;95%CI 0.71-1.56;P=.80;I2=0%)。致死性ICH总体风险无差异。

要点

  • 汇总分析显示DOACs与LMWH的ICH风险无显著差异(RR 0.65;95%CI 0.36-1.17;P=.15;I2=50%)。
  • 原发性脑癌患者中DOACs的ICH风险降低(RR 0.35;95%CI 0.18-0.69;P=.003;I2=0%)。
  • 转移性脑癌患者中抗凝药类型与ICH风险无关(RR 1.05;95%CI 0.71-1.56;P=.80;I2=0%)。

核心结论

  • 脑癌患者接受治疗性抗凝时,ICH风险因抗凝药种类及原发或转移性疾病诊断而异。

研究设计与样本

  • 荟萃分析与系统综述,检索PubMed、EMBASE和Cochrane数据库,纳入10项回顾性研究(n=1638)。
  • 通过计算风险比(RR)获得汇总统计量,采用I2统计量估计研究间异质性。

主要发现

  • DOACs组与LMWH组相比,ICH的汇总RR为0.65(95%CI 0.36-1.17;P=.15;I2=50%)。
  • 原发性脑癌研究中,DOACs组ICH风险降低(RR 0.35;95%CI 0.18-0.69;P=.003;I2=0%)。
  • 转移性脑癌患者中,抗凝药类型与ICH风险无差异(RR 1.05;95%CI 0.71-1.56;P=.80;I2=0%)。
  • 致死性ICH的总体风险在两种抗凝药之间无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The safety and efficacy of direct-acting oral anticoagulants (DOACs) for therapeutic anticoagulation in the setting of primary or metastatic brain cancer is not known. OBJECTIVES: To conduct a meta-analysis and systematic review of studies that compare the risk of intracranial hemorrhage (ICH) in patients with brain cancer treated with DOACs vs low-molecular-weight heparin (LMWH). METHODS: A literature search was conducted using PubMed, EMBASE, and Cochrane databases. Summary statistics were obtained by calculating the risk ratio (RR), and heterogeneity across studies was estimated using the I2 statistic. A total of 10 retrospective studies (n = 1638) met criteria for inclusion. The primary endpoint was the pooled RR for ICH in patients with brain tumors receiving anticoagulation with DOACs compared with those receiving LMWH. Secondary analyses included the risk of fatal ICH in each subgroup. RESULTS: The pooled RR for ICH in patients receiving DOACs vs those receiving LMWH was 0.65 (95% CI, 0.36-1.17; P = .15; I2 = 50%). In studies evaluating primary brain cancer, there was a reduction in risk of ICH with DOACs (RR, 0.35; 95% CI, 0.18-0.69; P = .003; I2 = 0%). In patients with metastatic brain cancer, there was no difference in the risk of ICH with the type of anticoagulation (RR, 1.05; 95% CI, 0.71-1.56; P = .80; I2 = 0%). The overall risk of fatal ICH was not different between anticoagulants. CONCLUSION: The risk of ICH in patients with brain cancer receiving therapeutic anticoagulation varies by anticoagulation agent and diagnosis of primary or metastatic disease.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Iyengar V, Agrawal S, Chiasakul T, et al. Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review. J Thromb Haemost. 2023. PMID: 37866517. doi:10.1016/j.jtha.2023.10.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。